Provided, inter alia, are thiosemicarbazone compounds, metal complexes of thiosemicarbazone compounds, pharmaceutical compositions, and methods for treating cancer.

Provided, inter alia, are thiosemicarbazone compounds, metal complexes of thiosemicarbazone compounds, pharmaceutical compositions, and methods for treating cancer.

Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets.

The present invention relates to sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds of the Formula:

##STR00001##

to pharmaceutical compositions comprising the compound and to the use of the compound for the treatment of certain diseases associated with elevated sodium and/or phosphate levels.

The present invention relates to sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds of the Formula:

##STR00001##

to pharmaceutical compositions comprising the compound and to the use of the compound for the treatment of certain diseases associated with elevated sodium and/or phosphate levels.

The present invention relates to the use of one or more particular dihydroisoquinolinium salts of formula (I) for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium salts and one or more chemical oxidizing agents. The present invention also relates to one or more particular dihydroisoquinolinium salts and also to compositions containing them, in particular compositions comprising a physiologically acceptable medium. ##STR00001##

The present invention relates to the use of one or more particular dihydroisoquinolinium salts of formula (I) for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium salts and one or more chemical oxidizing agents. The present invention also relates to one or more particular dihydroisoquinolinium salts and also to compositions containing them, in particular compositions comprising a physiologically acceptable medium. ##STR00001##

The present invention relates to a compound represented by the formula (1.sup.A). G represents a group selected from the group consisting of a monovalent group represented by the formula (G.sup.P) and a monovalent group represented by the formula (G.sup.S). R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, and R.sup.12 each independently represent a hydrogen atom or a group selected from the group consisting of an alkyl group, an alkenyl group, an aryl group, an aralkyl group, an alkoxy group, a halogeno group, and a halogeno alkyl group. ##STR00001##

A process that allows halogenation at the alpha-H position of alkylarenes, optionally further substituted on the aromatic or heteroaromatic ring, is described.